Preclinical Specificity and Activity of CABA-201, a Fully Human 41BB Containing CD19 CAR T Therapy for Treatment-Resistant Autoimmune Disease

Autoimmune diseases (AD) are common, with an incidence of 1 in 10 individuals. Most AD have standardized treatment regimens, but no curative therapy. Treatment consists of immunosuppressive therapy with associated toxicity. Targeted biologic therapies directed at cytokine pathways, costimulatory molecules, and B cells are also utilized but are limited by need for frequent infusions and high cost and incidence of adverse events. There is increasing evidence that B cells play a central role in AD pathogenesis, based upon responsiveness to B cell depletion with antibody-based therapeutics, but responses are typically transient, partly due to the incomplete depletion of B cells in secondary lymphoid tissues.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Joel Weinthal, Jason Peng, Andrea Alvarado, Hangameh Cassim, Willis Jonathan, Julia SantaMaria, Ashley Martynchuk, Victoria Stratton, Steven Wong, Darshil Patel, Chien-Chung Chen, Yan Li, Gwendolyn Binder, Rebecca Dryer-Minnerly, Samik Basu, Jinmin Lee Tags: 196 Source Type: research